|Videos|December 15, 2016

Potential Source of Stem Cells

Research in a mouse model identified a source of stem cells in the meninges.

In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a study in a mouse model that identified a source of stem cells in the meninges. The cells migrated from the meninges to the cortex in the neonatal brain and differentiated into functional cortical neurons.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related to this article

October 5th, 2026

Phase 1 Data Link ARV-102 LRRK2 Degradation to Oculomotor and CSF Biomarker Changes in Parkinson Disease

Early phase 1 findings showed that the PROTAC LRRK2 degrader ARV-102 was associated with improvements in saccadic hypometria and changes in CSF markers of endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance in participants with Parkinson disease.

October 5th, 2026

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease

Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.

October 5th, 2026

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses

New analyses from the D1AMOND clinical program found that 69.8% of participants achieved a clinically meaningful reduction in tic severity within 8 weeks of ecopipam treatment, while an interim 18-month analysis showed sustained improvement without new safety signals.

October 5th, 2026

This Week on NeurologyLive® — October 5, 2026

Here's some of what is coming soon to NeurologyLive® this week.

October 4th, 2026

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis

PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized myasthenia gravis.

October 4th, 2026

NeurologyLive® Brain Games: October 4, 2026

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!

October 3rd, 2026

Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype

New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later.

October 3rd, 2026

Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows

A new Bayesian network meta-analysis found nipocalimab's serious adverse event rates compared favorably with other gMG therapies, while overall adverse event rates were comparable.

Potential Source of Stem Cells

Related to this article

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Phase 3 PROPEL Trial to Test Imeroprubart in Generalized Myasthenia Gravis

LRRK2 Inhibitor BIIB122 Fails to Slow Early-Stage Parkinson Disease

Ecopipam Shows Early and Sustained Tic Reduction in New Pediatric Tourette Syndrome Analyses

Early Spinal Muscular Atrophy Treatment Tied to Milder Pediatric Phenotype

Nipocalimab’s Safety Profile Slightly Favored Over Other Myasthenia Gravis Therapies, Indirect Comparison Shows